European agency rules against stem cell patents

LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes.

An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by the Wisconsin Alumni Research Foundation in 1995.

Stem cells taken from days-old embryos work as a type of master cell for the body capable of changing into many types of tissues and cells.

Opponents call the research immoral because it requires the destruction of the embryo but advocates say it is the best hope for potential cures for conditions such as diabetes, Parkinson’s disease and spinal cord injuries.

The problem for companies looking to profit from technology using stem cells is that without patent protection there is little incentive to pour money into research.

“European patent law prohibits the patenting of human stem cell cultures whose preparation necessarily involves the destruction of human embryos,” the European Patent Office said in a statement.

“That is the decision reached by the Enlarged Board of Appeal of the European Patent Office (EPO).”

University of Wisconsin researcher James Thomson was the first to isolate embryonic stem cells in 1988, a discovery that was later patented.

But that patent and others related to it held by the Wisconsin Alumni Research Foundation had been challenged.

The board’s decision to uphold the earlier ruling could keep some companies from jumping into the sector and steer investors to put their money elsewhere.

In the United States, companies like Geron Corp have been granted patents on certain types of human embryonic stem cell growth technology.

(Reporting by Michael Kahn; Editing by Elaine Hardcastle)


Related Posts:

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Stem cell advocates and researchers are eagerly awaiting the moment next year when president-elect Barack Obama rescinds a directive that limits federal funding of human embryonic stem-cell research. The directive was one of President George W. Bush’s first major acts after taking office in 2001, and Obama

Full Post: Stem cell supporters await their Obama moment

By Esha Dey BANGALORE (Reuters) - Shares of companies developing therapies based on stem cells surged on Monday, after confirmation over the weekend that U.S. president-elect Barack Obama plans to reverse an existing executive order against federal funding of embryonic stem-cell research. Companies such as Geron Corp and StemCells Inc saw a sharp rise in their stock

Full Post: Stem-cell firms surge as Obama fuels funding hopes

By Ben Hirschler LONDON (Reuters) - Danish drugmaker Novo Nordisk A/S is turning to stem cells in the hunt for a cure for diabetes. The world leader in diabetes care said on Thursday it had launched a new collaboration to develop a treatment for type 1 diabetes by programing stem cells to turn into insulin-producing cells. The alliance

Full Post: Novo taps stem cells in hunt for diabetes cure

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Rogue clinics around the world may be exploiting hope and ignorance by offering unproven stem cell therapies, a group of stem cell experts said in a report released on Wednesday. The International Society for Stem Cell Research released guidelines for researchers and regulators, and a guidebook for

Full Post: “Rogue” stem cell clinics exploit hope: report

WASHINGTON (Reuters) - The U.S. Food and Drug Administration has cleared the way for the world’s first study of human embryonic stem cell therapy, Geron Corp said on Friday. The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord

Full Post: FDA allows first test of human stem cell therapy

Site Navigation

Most Read